Natus Medical Incorporated
Vimab Group AB (publ), together with its subsidiaries, operates in the energy service, and industrial and environmental technology industries in Sweden and internationally. The company sells energy storage systems and fittings, as well as valve or spare part; and manufactures various products, such as portable valve grinding equipment, electric steam boilers, customized steam systems, molds, tool… Read more
Natus Medical Incorporated (NM4) - Net Assets
Latest net assets as of September 2025: €-7.13 Million EUR
Based on the latest financial reports, Natus Medical Incorporated (NM4) has net assets worth €-7.13 Million EUR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€249.32 Million) and total liabilities (€256.45 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-7.13 Million |
| % of Total Assets | -2.86% |
| Annual Growth Rate | -25.84% |
| 5-Year Change | -95.68% |
| 10-Year Change | -95.46% |
| Growth Volatility | 39.87 |
Natus Medical Incorporated - Net Assets Trend (2014–2024)
This chart illustrates how Natus Medical Incorporated's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Natus Medical Incorporated (2014–2024)
The table below shows the annual net assets of Natus Medical Incorporated from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €17.75 Million | -79.49% |
| 2023-12-31 | €86.54 Million | +52.30% |
| 2022-12-31 | €56.82 Million | -86.62% |
| 2021-12-31 | €424.75 Million | +3.32% |
| 2020-12-31 | €411.09 Million | -1.21% |
| 2019-12-31 | €416.12 Million | +4.44% |
| 2018-12-31 | €398.44 Million | -5.60% |
| 2017-12-31 | €422.10 Million | +1.13% |
| 2016-12-31 | €417.37 Million | +6.82% |
| 2015-12-31 | €390.71 Million | +10.77% |
| 2014-12-31 | €352.71 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Natus Medical Incorporated's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €17.75 Million | 100.00% |
| Total Equity | €17.75 Million | 100.00% |
Natus Medical Incorporated Competitors by Market Cap
The table below lists competitors of Natus Medical Incorporated ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Adgar Investments and Development Ltd
TA:ADGR
|
$2.29 Million |
|
Pasdec Holdings Bhd
KLSE:6912
|
$2.29 Million |
|
Tongda Group Holdings Limited
F:TJC
|
$2.29 Million |
|
AXMIN Inc
PINK:AXMIF
|
$2.29 Million |
|
UV GERMI S.A. EO -15
F:1NY
|
$2.29 Million |
|
MANTLE MINERALS
F:MXB0
|
$2.29 Million |
|
Welsis Corp.
OTCGREY:WLSS
|
$2.29 Million |
|
Marley Spoon Group SE
XETRA:MS1
|
$2.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Natus Medical Incorporated's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 78,658,000 to 17,745,000, a change of -60,913,000 (-77.4%).
- Net loss of 76,941,000 reduced equity.
- New share issuances of 972,000 increased equity.
- Other factors increased equity by 15,056,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-76.94 Million | -433.59% |
| Share Issuances | €972.00K | +5.48% |
| Other Changes | €15.06 Million | +84.85% |
| Total Change | €- | -77.44% |
Book Value vs Market Value Analysis
This analysis compares Natus Medical Incorporated's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.47x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.03x to 0.47x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | €12.74 | €0.35 | x |
| 2018-12-31 | €11.79 | €0.35 | x |
| 2019-12-31 | €12.19 | €0.35 | x |
| 2020-12-31 | €12.12 | €0.35 | x |
| 2021-12-31 | €12.41 | €0.35 | x |
| 2022-12-31 | €2.93 | €0.35 | x |
| 2023-12-31 | €3.52 | €0.35 | x |
| 2024-12-31 | €0.74 | €0.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Natus Medical Incorporated utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -433.59%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -23.78%
- • Asset Turnover: 1.23x
- • Equity Multiplier: 14.85x
- Recent ROE (-433.59%) is below the historical average (-44.13%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 9.21% | 9.13% | 0.82x | 1.23x | €-2.79 Million |
| 2015 | 9.71% | 10.09% | 0.78x | 1.23x | €-1.15 Million |
| 2016 | 10.21% | 11.15% | 0.59x | 1.55x | €856.60K |
| 2017 | -4.81% | -4.05% | 0.71x | 1.68x | €-62.50 Million |
| 2018 | -5.76% | -4.32% | 0.83x | 1.60x | €-62.78 Million |
| 2019 | -3.77% | -3.16% | 0.80x | 1.50x | €-57.28 Million |
| 2020 | -4.04% | -4.00% | 0.69x | 1.46x | €-57.72 Million |
| 2021 | 3.10% | 2.78% | 0.84x | 1.33x | €-29.30 Million |
| 2022 | -60.23% | -15.22% | 1.15x | 3.45x | €-39.90 Million |
| 2023 | -5.41% | -1.25% | 1.01x | 4.31x | €-12.12 Million |
| 2024 | -433.59% | -23.78% | 1.23x | 14.85x | €-78.72 Million |
Industry Comparison
This section compares Natus Medical Incorporated's net assets metrics with peer companies in the Consulting Services industry.
Industry Context
- Industry: Consulting Services
- Average net assets among peers: $422,744,115
- Average return on equity (ROE) among peers: -73.81%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Natus Medical Incorporated (NM4) | €-7.13 Million | 9.21% | N/A | $2.29 Million |
| Palgon AG (3D6) | $151.52K | -61.78% | 0.06x | $55.05K |
| Rejlerkoncernen AB (3RE) | $1.94 Billion | 11.45% | 0.91x | $274.54 Million |
| RC Fornax Plc (8AD) | $108.00K | 533.33% | 12.88x | $670.36K |
| Avemio AG (AV2) | $161.06K | -862.69% | 0.03x | $5.08K |
| Ricardo plc (RIR) | $176.50 Million | 10.65% | 0.92x | $168.54 Million |